Pfizer will set up an innovation hub on Swansea University’s £450m Bay Campus. Credit: Wikimedia Commons/Swanseauni

Pfizer and Swansea University have formalised a collaboration aimed at improving the health and wellbeing of the people of South West Wales.

Speaking to delegates during a keynote speech at this year’s BioWales conference, spokespeople from both Pfizer and the University of Swansea confirmed that the collaboration has been formalised, and that they ‘look forward to working together to share knowledge and experience’.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Originally launched at the 2017 conference, the collaboration will involve Pfizer setting up an innovation hub at the School of Management on Swansea University’s £450m Bay Campus. The aim of the hub is to share knowledge, skills and expertise to develop a health system that works with industry, the NHS and academia to improve healthcare in the region. The pharmaceutical giant will also work with academics from the Institute of Life Science at Swansea University’s Singleton Campus medical school.

The collaboration will incorporate ‘a range of therapeutic and technology-based interventions that will be studied through the collection of real-world data’.

“Our aim is to develop innovative approaches to improve patient outcomes, support long-term sustainability of the NHS and maintain a thriving life sciences industry in the UK,” said Pfizer UK managing director Erik Nordkamp.

“Our aim is to develop innovative approaches to improve patient outcomes, support long-term sustainability of the NHS and maintain a thriving life sciences industry in the UK.”

“With Swansea University, we recognise South West Wales as a region with the potential to be at the forefront of excellence in healthcare service delivery, research, education and innovation.”

The collaboration will also help deliver elements of the £1.3bn Swansea Bay City Region City Deal ─ a project funded by public and private investors aimed at strengthening the health, energy and manufacturing sectors in Swansea and the surrounding areas.

“One of the aims of the City Deal is to create a ‘living laboratory’ in this region for health, wellbeing and life sciences,” said Swansea University vice-president Professor Marc Clement. “This regional vision is strongly aligned with the UK Government’s recent Life Science Industrial Strategy.

“We see this collaboration with Pfizer as a real opportunity to operationalise our vision and aims with purpose and pace.”

In 2016, technology company Fujitsu opened an education innovation hub on the Swansea Bay Campus. In the same year the Bevan Commission, which provides guidance to the Minister for Health and Social Services on health and healthcare in Wales, relocated its headquarters to the campus.